Zheng Quan Ri Bao Wang·2025-07-27 12:42Core Viewpoint - The biopharmaceutical industry in the Shenzhen Stock Exchange is showing a stable and positive performance in the first half of 2025, with 56 companies expected to achieve a net profit between 3.8 billion to 5 billion yuan [1] Group 1: Performance Forecasts - Dabo Medical is expected to achieve a net profit of approximately 230 million to 250 million yuan, representing a year-on-year increase of 66.37% to 80.84% [2] - Aosaikang is projected to realize a net profit of 135 million to 175 million yuan, with a year-on-year growth rate of 78.58% to 131.50% [2] - Jilin Aodong anticipates a net profit of about 1.236 billion to 1.290 billion yuan, reflecting a year-on-year increase of 130% to 140% [3] Group 2: Innovation and R&D - Dabo Medical emphasizes product innovation and international development strategies to maintain healthy business growth [2] - Aosaikang is focusing on the commercialization of its first innovative drug, which marks a significant milestone in its transformation [2] - Aosaikang has over 40 drugs in various stages of development, including more than ten innovative drugs in clinical stages [5] Group 3: Strategic Adjustments - Companies are actively adjusting their operational strategies and optimizing cost structures to enhance resilience and profitability [4] - Dabo Medical plans to strengthen its core business through innovation and international expansion [4] - Jilin Aodong aims to focus on its pharmaceutical core business while leveraging its brand advantages for steady revenue and profit growth [4]